JP2016513456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513456A5 JP2016513456A5 JP2015562469A JP2015562469A JP2016513456A5 JP 2016513456 A5 JP2016513456 A5 JP 2016513456A5 JP 2015562469 A JP2015562469 A JP 2015562469A JP 2015562469 A JP2015562469 A JP 2015562469A JP 2016513456 A5 JP2016513456 A5 JP 2016513456A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- wnt inhibitor
- biomarker
- gene expression
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776334P | 2013-03-11 | 2013-03-11 | |
| US61/776,334 | 2013-03-11 | ||
| PCT/IB2014/059585 WO2014141038A2 (en) | 2013-03-11 | 2014-03-10 | Markers associated with wnt inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513456A JP2016513456A (ja) | 2016-05-16 |
| JP2016513456A5 true JP2016513456A5 (enExample) | 2017-04-06 |
| JP6445984B2 JP6445984B2 (ja) | 2018-12-26 |
Family
ID=50382514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562469A Active JP6445984B2 (ja) | 2013-03-11 | 2014-03-10 | Ｗｎｔ阻害剤に関連するマーカー |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10422007B2 (enExample) |
| EP (1) | EP2972372B1 (enExample) |
| JP (1) | JP6445984B2 (enExample) |
| KR (1) | KR102194746B1 (enExample) |
| CN (1) | CN105190313B (enExample) |
| AU (1) | AU2014229424B2 (enExample) |
| BR (1) | BR112015019567A8 (enExample) |
| CA (1) | CA2903976C (enExample) |
| CL (1) | CL2015002572A1 (enExample) |
| DK (1) | DK2972372T3 (enExample) |
| ES (1) | ES2681618T3 (enExample) |
| HU (1) | HUE039776T2 (enExample) |
| IL (1) | IL240794A (enExample) |
| MA (1) | MA38395B1 (enExample) |
| MX (1) | MX2015012534A (enExample) |
| PH (1) | PH12015501778A1 (enExample) |
| PL (1) | PL2972372T3 (enExample) |
| PT (1) | PT2972372T (enExample) |
| RU (2) | RU2663701C2 (enExample) |
| SG (1) | SG11201505873VA (enExample) |
| SI (1) | SI2972372T1 (enExample) |
| TN (1) | TN2015000325A1 (enExample) |
| TW (1) | TWI582239B (enExample) |
| WO (1) | WO2014141038A2 (enExample) |
| ZA (1) | ZA201505227B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015119552B4 (de) * | 2015-10-23 | 2022-06-15 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Monoterpenhaltige Zusammensetzung zur Behandlung von Tumor- und/oder Krebserkrankungen |
| CN105617359A (zh) * | 2015-12-31 | 2016-06-01 | 中国科学院成都生物研究所 | Wnt信号通路蛋白Frzb在制备抗肝癌药中的应用 |
| WO2017167150A1 (zh) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | 一种3-氟吡啶杂环化合物及其应用 |
| CN106434968B (zh) * | 2016-11-18 | 2019-10-22 | 北京致成生物医学科技有限公司 | Ccdc168作为标记物在检测胰腺癌试剂中的应用 |
| TWI846703B (zh) | 2018-06-19 | 2024-07-01 | 日商武田藥品工業股份有限公司 | 癌症治療方法 |
| US12195804B2 (en) | 2018-08-07 | 2025-01-14 | Board Of Regents, The University Of Texas System | Treatment of squamous cell carcinoma |
| EP3833784A1 (en) * | 2018-08-07 | 2021-06-16 | PIQUR Therapeutics AG | Treatment of squamous cell carcinoma |
| EP4182479A1 (en) * | 2020-07-15 | 2023-05-24 | Université Libre de Bruxelles | Method for determining sensitivity to an antineoplastic agent |
| CN116808027B (zh) * | 2023-05-30 | 2025-08-29 | 重庆医科大学附属第一医院 | 化合物或其盐在制备抑制wnt7a基因活性的制剂中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US6387657B1 (en) * | 1997-10-29 | 2002-05-14 | Genentech, Inc. | WISP polypeptides and nucleic acids encoding same |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| AU2004291709C1 (en) | 2003-05-30 | 2010-03-11 | Astrazeneca Uk Limited | Process |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| WO2006052128A1 (en) | 2004-11-10 | 2006-05-18 | Hubrecht Laboratorium | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| EP2083088A3 (en) * | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
| WO2009074968A2 (en) * | 2007-12-12 | 2009-06-18 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for predicting the efficacy of cancer therapy |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| CA2776278A1 (en) | 2009-10-02 | 2011-04-07 | Cylene Pharmaceuticals, Inc. | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2549399A1 (en) * | 2011-07-19 | 2013-01-23 | Koninklijke Philips Electronics N.V. | Assessment of Wnt pathway activity using probabilistic modeling of target gene expression |
-
2014
- 2014-03-07 TW TW103108007A patent/TWI582239B/zh not_active IP Right Cessation
- 2014-03-10 HU HUE14712783A patent/HUE039776T2/hu unknown
- 2014-03-10 ES ES14712783.1T patent/ES2681618T3/es active Active
- 2014-03-10 CA CA2903976A patent/CA2903976C/en active Active
- 2014-03-10 JP JP2015562469A patent/JP6445984B2/ja active Active
- 2014-03-10 WO PCT/IB2014/059585 patent/WO2014141038A2/en not_active Ceased
- 2014-03-10 PL PL14712783T patent/PL2972372T3/pl unknown
- 2014-03-10 KR KR1020157024490A patent/KR102194746B1/ko not_active Expired - Fee Related
- 2014-03-10 AU AU2014229424A patent/AU2014229424B2/en not_active Ceased
- 2014-03-10 MA MA38395A patent/MA38395B1/fr unknown
- 2014-03-10 PT PT147127831T patent/PT2972372T/pt unknown
- 2014-03-10 RU RU2015138688A patent/RU2663701C2/ru active
- 2014-03-10 EP EP14712783.1A patent/EP2972372B1/en active Active
- 2014-03-10 SG SG11201505873VA patent/SG11201505873VA/en unknown
- 2014-03-10 SI SI201430805T patent/SI2972372T1/sl unknown
- 2014-03-10 US US14/774,212 patent/US10422007B2/en active Active
- 2014-03-10 DK DK14712783.1T patent/DK2972372T3/en active
- 2014-03-10 MX MX2015012534A patent/MX2015012534A/es unknown
- 2014-03-10 RU RU2017141378A patent/RU2017141378A/ru not_active Application Discontinuation
- 2014-03-10 BR BR112015019567A patent/BR112015019567A8/pt not_active Application Discontinuation
- 2014-03-10 CN CN201480014311.1A patent/CN105190313B/zh not_active Expired - Fee Related
-
2015
- 2015-07-20 ZA ZA2015/05227A patent/ZA201505227B/en unknown
- 2015-07-31 TN TN2015000325A patent/TN2015000325A1/en unknown
- 2015-08-12 PH PH12015501778A patent/PH12015501778A1/en unknown
- 2015-08-24 IL IL240794A patent/IL240794A/en active IP Right Grant
- 2015-09-10 CL CL2015002572A patent/CL2015002572A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Caraco et al. | Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults | |
| Dow et al. | Integrative genomic analysis of mouse and human hepatocellular carcinoma | |
| Harding et al. | Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies | |
| Awad et al. | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis | |
| Khunger et al. | Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience | |
| Watson et al. | The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF | |
| Long et al. | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | |
| Vogler et al. | Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies–from pathogenesis to treatment | |
| RU2017120287A (ru) | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 | |
| Sullivan et al. | MAP kinase signaling and inhibition in melanoma | |
| Suh et al. | Clinical update on cancer: molecular oncology of head and neck cancer | |
| Vale | Targeting the JAK-STAT pathway in the treatment of ‘Th2-high’severe asthma | |
| Patel et al. | Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma | |
| Sauler et al. | Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease | |
| Cadavid et al. | Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis | |
| Radonjic-Hoesli et al. | Novel targeted therapies for eosinophil-associated diseases and allergy | |
| Patel et al. | Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition | |
| TW201414475A (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Hucthagowder et al. | Utility of clinical high‐depth next generation sequencing for somatic variant detection in the PIK3CA‐related overgrowth spectrum | |
| RU2015138688A (ru) | Маркеры, ассоциированные с ингибиторами wnt | |
| Braido et al. | Phenotypes/endotypes-driven treatment in asthma | |
| Antonello et al. | Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF | |
| JP2015526074A5 (enExample) | ||
| Mangana et al. | Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland | |
| Brilha et al. | Early secretory antigenic target-6 drives matrix metalloproteinase-10 gene expression and secretion in tuberculosis |